Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors.
Robert Lance Fine
No relevant relationships to disclose
Anthony Paul Gulati
No relevant relationships to disclose
Dawn Tsushima
No relevant relationships to disclose
Kelley B. Mowatt
No relevant relationships to disclose
Anna Oprescu
No relevant relationships to disclose
Jeffrey N. Bruce
No relevant relationships to disclose
John A. Chabot
No relevant relationships to disclose